← Oncology Approval Tracker

FDA DECISION ·

Polivy + R-CHP

polatuzumab vedotin-piiq + rituximab product + cyclophosphamide + doxorubicin + prednisone · Genentech

FDA approvalNew or expanded indicationLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with previously untreated DLBCL not otherwise specified or high-grade B-cell lymphoma and an International Prognostic Index score of at least 2.

LAMPGEN ANALYSIS

Why it matters

The expansion introduced polatuzumab into a first-line regimen for higher-risk disease.

What research teams should watch

Capture the IPI score and reconcile the exact regimen before drug preparation and monitoring.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Frontline DLBCL

PRIMARY RECORDS

Sources